H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600

On February 26, 2026, H.C. Wainwright raised the terms people connected United Therapeutics Corporation (NASDAQ:UTHR) from $525 to $600 portion maintaining a Buy rating. The institution has announced that it is processing a brushed mist inhaler for treprostinil, slated for a 2027 motorboat to dainty PAH and PH-ILD. In the expert note, H.C. Wainwright sees this arsenic a strategical determination to antagonistic competitors similar Yutrepia portion evolving the Tyvaso franchise. The absorption reaffirmed its people of a $4 cardinal gross tally complaint by precocious 2027, portion it awaits the upcoming Phase 3 information for ralinepag and IPF treatments. The steadfast anticipates upside to this target.

On the aforesaid day, RBC Capital expert Lisa Walter besides raised United Therapeutics Corporation’s (NASDAQ:UTHR) people terms from $587 to $643 portion keeping an Outperform standing connected the stock. Similar to H.C. Wainwright, RBC Capital expert besides cited the caller announcement for a brushed mist inhaler for Treprostinil that could beryllium preferred implicit DPIs.

Founded successful 1996, United Therapeutics Corporation (NASDAQ:UTHR) is simply a biotechnology institution focused connected uncommon diseases specified arsenic pulmonary arterial hypertension. Its co-headquarters are successful Maryland and North Carolina.

While we admit the imaginable of UTHR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Stocks to Buy successful 2026 According to Reddit and 13 High-Quality S&P 500 Financial Stocks According to Hedge Funds.

Disclosure. None. Follow Insider Monkey connected Google News.